Morgan Stanley GIFT Cures℠ powered by Harrington Discovery Institute was established in 2019 as the first special interest program of Morgan Stanley Global Impact Funding Trust (GIFT) in response to client demands for concrete results and outcomes from their philanthropy in disease research. As patients and their families look to be part of the solution through their charitable donations, the field of philanthropy in particular has played a large role in advancing medical discoveries.
The Morgan Stanley GIFT Cures program provides opportunities for new and veteran philanthropists to combine their resources to magnify the impact of their medically related giving, whether they wish to focus on a specific disease or across a broader spectrum. It is an opportunity for philanthropists, foundations, family offices and companies interested in learning collaboratively from drug development experts and providing catalytic support to bring cures and treatments to market.
"Harrington Discovery Institute has the right combination of philanthropy, pharma and investing. Its ability to accelerate the drug development process by ensuring that the world's best discoveries turn into next-generation medicines and fill unmet needs made it the ideal partner."
Melanie Schnoll Begun
Managing Director, Head of Philanthropy Management
President, Morgan Stanley GIFT Cures
Photo: Melanie Schnoll Begun, 2019 Harrington Scientific Symposium
“We are pleased to collaborate with Morgan Stanley GIFT Cures to grow the community of philanthropists who are committed to supporting the development of new medicines. From the start, we knew that strategic partnerships like this would be instrumental in helping expand Harrington Discovery Institute’s portfolio of drugs-in-the-making and increase its impact on human health.”
Ronald G. Harrington
Entrepreneur and Philanthropist
Photo: Ron and Nancy Harrington
In honor of Rare Disease Day 2022, The Oxford-Harrington Rare Disease Centre (OHC) hosted a Rare Disease Day Webinar, Advancing Novel Treatments for Neurological Rare Diseases, on Monday, February 28. The OHC was formed in 2019 through a unique partnership between Harrington Discovery Institute and The University of Oxford to blend science, discovery, and development to address the unmet need in rare disease across the globe to deliver major clinical impact for patients.
The goal of the OHC is to find cures that help patients and families. These patients and families have names and faces, as demonstrated by powerful testimony offered by the Cooper & New family.
Friends of Harrington Discovery Institute, who connected with us in 2019 through Morgan Stanley GIFT Cures, a unique philanthropic opportunity, are Rusty Cooper, his wife Liz, alongside Rusty’s son-in-law, Jordan New, and Rusty’s daughter, Sophie.
Rusty Cooper, a financial advisor at Morgan Stanley, is a wonderful advocate for rare disease treatments, as his grandson, Cooper, was diagnosed with an ultra-rare disease. Rusty and his son-in-law, Jordan New, and their family shared their story of how the work of The Oxford-Harrington Rare Disease Centre offers them hope.
To learn more and to become involved in our work creating cures, contact Tyrone Gorden, Vice President of Global Development, at Tyrone.Gorden@HarringtonDiscovery.org.